GNNSF News and Press, Genscript Biotech Corp

2024-03-20 07:15:00 ET Summary GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction. Legend Biotech continues to invest in R&D to expand the number of indications that Carvykti can t...

2024-03-11 12:49:59 ET More on Genscript Biotech GenScript Biotech Corporation (GNNSF) Q4 2023 Earnings Call Transcript Historical earnings data for Genscript Biotech Read the full article on Seeking Alpha For further details see: Genscript Biotech GAAP E...

2024-03-11 10:10:21 ET GenScript Biotech Corporation (GNNSF) Q4 2023 Results Conference Call March 10, 2024 07:15 PM ET Company Participants Sherry Shao - Rotating CEO Shiniu Wei - CFO Li Chen - ProBio, CEO Patrick Liu - Chairman of ProBio Ying Huang - CE...

2024-02-25 05:00:00 ET Summary AlphaGen Therapeutics and ArtBio, two targeted RLT companies, forged a far-reaching agreement to expand ArtBio’s market and develop new RLTs. Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences, granting acces...

2023-08-21 18:04:03 ET GenScript Biotech Corporation (GNNSF) Q2 2023 Earnings Conference Call August 20, 2023, 07:30 PM ET Company Participants Duan Pengfei - IR Director Robin Meng - Chair of the Board Sherry Shao - Rotating CEO Patrick Liu - Off-duty Rotati...

2023-03-31 06:28:30 ET Genscript Biotech press release ( OTCPK:GNNSF ): FY GAAP EPS of -$10.82. Revenue of $625.7M (+27.7% Y/Y) misses by $94.03M . The adjusted net profit of non-cell therapy business before eliminations was approximately US$62.4 million, representing ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) all fell...

Summary After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech. Some analysts believe Genscript may have become profitable last year, but also worry over its mounting R&D and sa...

Summary Shanghai Mabwell Biosciences out-licensed global rights (ex-China) for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Aprinoia Therapeutics, a company developing products for neurodegenerative diseases, agreed to merge with SPAC Ross Acquisi...

Summary Chengdu WestGene Biopharma completed a $21 million Series A Round to advance its portfolio of nearly 20 mRNA candidates, including its lead COVID-19 vaccine, which is in IND stage. Suzhou GenAssist Therapeutics raised “millions of dollars” in an A round to support ...